Single User License
INR 238070
Site License
INR 476140
Corporate User License
INR 714210

Service Tax Additional

select a format
Price

Single User License
USD 3500
Site License
USD 7000
Corporate User License
USD 10500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98)-Pipeline Review, H2 2016

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98)-Pipeline Review, H2 2016


  Request for Sample Report

Executive Summary

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98)-Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98)-Pipeline Review, H2 2016', provides in depth analysis on Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted pipeline therapeutics.

The report provides comprehensive information on the Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98)

The report reviews Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects

The report assesses Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) Overview 8

Therapeutics Development 9

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98)-Products under Development by Stage of Development 9

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98)-Products under Development by Therapy Area 10

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98)-Products under Development by Indication 11

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98)-Pipeline Products Glance 13

Late Stage Products 13

Early Stage Products 14

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98)-Products under Development by Companies 15

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98)-Products under Development by Universities/Institutes 21

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98)-Therapeutics Assessment 23

Assessment by Monotherapy/Combination Products 23

Assessment by Mechanism of Action 24

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98)-Companies Involved in Therapeutics Development 29

4SC AG 29

Acetylon Pharmaceuticals, Inc. 30

Chipscreen Biosciences Ltd 31

Curis, Inc. 32

GlaxoSmithKline Plc 33

HitGen LTD 34

IRBM Science Park SpA 35

Italfarmaco S.p.A. 36

MEI Pharma, Inc. 37

Merck & Co., Inc. 38

Mirati Therapeutics Inc. 39

Oncolys BioPharma Inc 40

Sigma-Tau S.p.A. 41

Syndax Pharmaceuticals Inc 42

TetraLogic Pharmaceuticals 43

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98)-Drug Profiles 44

4SC-202-Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

ACY-738-Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

ACY-957-Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

crocetin-Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

CS-3158-Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

CUDC-907-Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

entinostat-Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

givinostat-Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

HG-3001-Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

Largazole-Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

mocetinostat-Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

OBP-801-Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

pracinostat-Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

remetinostat-Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

Small Molecule to Inhibit HDAC1, HDAC3 and HDAC6 for Lung Adenocarcinoma-Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

Small Molecule to Inhibit Histone Deacetylase 1 for Beta Thalassemia-Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

Small Molecule to Inhibit Histone Deacetylases for Oncology-Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

Small Molecules to Inhibit BRD4 and HDAC1 for Oncology-Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

Small Molecules to Inhibit HDAC1, HDAC2 and HDAC3 for Oncology-Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

ST-3595-Drug Profile 87

Product Description 87

Mechanism Of Action 87

R&D Progress 87

tucidinostat-Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

vorinostat-Drug Profile 91

Product Description 91

Mechanism Of Action 91

R&D Progress 91

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98)-Dormant Projects 95

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98)-Featured News & Press Releases 99

Aug 01, 2016: MEI Pharmas Pracinostat Receives Breakthrough Therapy Designation from FDA for Treatment in Combination with Azacitidine of Patients with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Chemotherapy 99

Jun 08, 2016: Curis Announces Oral Presentation of Clinical Data Update from the Phase 1 Study of CUDC-907 at the 21st Congress of the European Hematology Association 99

Jun 05, 2016: Mirati Therapeutics Provides Update On Mocetinostat Program 100

Jun 02, 2016: Curis Announces Presentations Related to CUDC-907 at 2016 ASCO Annual Meeting 100

May 18, 2016: Entinostat Data to be Highlighted at the American Society of Clinical Oncology 2016 Annual Meeting 100

May 04, 2016: Acetylon Pharmaceuticals Publishes New Mechanism for the Treatment of Sickle Cell Disease/Beta-Thalassemia with Selective HDAC1/2 Inhibition in PLoS One 101

Apr 11, 2016: Syndax Announces Entinostat Data to be Presented at the American Association for Cancer Research (AACR) 2016 Annual Meeting 102

Apr 11, 2016: Curis Announces Presentation of Preclinical Data for CUDC-907 at AACR Annual Meeting 104

Apr 04, 2016: Curis Announces Publication of CUDC-907 Phase 1 Clinical Trial Data in Lancet Oncology 104

Mar 24, 2016: Mirati Therapeutics To Present Mocetinostat Preclinical Data At 2016 American Association For Cancer Research Annual Meeting 104

Mar 21, 2016: Epigenetic compound 4SC-202 strengthens endogenous immune response to cancer 105

Mar 03, 2016: HUYA Bioscience International Expands Senior Management Team 105

Dec 22, 2015: Huya Bioscience International Announces Orphan Drug Designation For HBI-8000 In Japan 106

Dec 07, 2015: MEI Pharma Announces Positive Results from Phase II Study of Pracinostat in Acute Myeloid Leukemia, Plans to Initiate Phase III Registration Study 106

Dec 07, 2015: Acetylon Presents Data on the Pharmacokinetics and HbE/HbG Hemoglobin Induction Following Once Daily Dosing of an Oral HDAC1,2 Inhibitor in Animal Models 107

Appendix 109

Methodology 109

Coverage 109

Secondary Research 109

Primary Research 109

Expert Panel Validation 109

Contact Us 109

Disclaimer 110

List of Figures

Number of Products under Development for, H2 2016 9

Number of Products under Development by Therapy Area, H2 2016 10

Number of Products under Development by Top 10 Indication, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 13

Comparative Analysis by Early Stage Products, H2 2016 14

Assessment by Monotherapy/Combination Products, H2 2016 23

Number of Products by Stage and Mechanism of Actions, H2 2016 24

Number of Products by Routes of Administration, H2 2016 25

Number of Products by Stage and Routes of Administration, H2 2016 25

Number of Products by Molecule Types, H2 2016 27

Number of Products by Stage and Molecule Type, H2 2016 27

List of Tables

Number of Products under Development for, H2 2016 9

Number of Products under Development by Therapy Area, H2 2016 10

Number of Products under Development by Indication, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 13

Comparative Analysis by Early Stage Products, H2 2016 14

Number of Products under Development by Companies, H2 2016 15

Products under Development by Companies, H2 2016 16

Products under Development by Companies, H2 2016 (Contd..1) 17

Products under Development by Companies, H2 2016 (Contd..2) 18

Products under Development by Companies, H2 2016 (Contd..3) 19

Products under Development by Companies, H2 2016 (Contd..4) 20

Number of Products under Investigation by Universities/Institutes, H2 2016 21

Products under Investigation by Universities/Institutes, H2 2016 22

Assessment by Monotherapy/Combination Products, H2 2016 23

Number of Products by Stage and Mechanism of Action, H2 2016 24

Number of Products by Stage and Route of Administration, H2 2016 26

Number of Products by Stage and Molecule Type, H2 2016 28

Pipeline by 4SC AG, H2 2016 29

Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016 30

Pipeline by Chipscreen Biosciences Ltd, H2 2016 31

Pipeline by Curis, Inc., H2 2016 32

Pipeline by GlaxoSmithKline Plc, H2 2016 33

Pipeline by HitGen LTD, H2 2016 34

Pipeline by IRBM Science Park SpA, H2 2016 35

Pipeline by Italfarmaco S.p.A., H2 2016 36

Pipeline by MEI Pharma, Inc., H2 2016 37

Pipeline by Merck & Co., Inc., H2 2016 38

Pipeline by Mirati Therapeutics Inc., H2 2016 39

Pipeline by Oncolys BioPharma Inc, H2 2016 40

Pipeline by Sigma-Tau S.p.A., H2 2016 41

Pipeline by Syndax Pharmaceuticals Inc, H2 2016 42

Pipeline by TetraLogic Pharmaceuticals, H2 2016 43

Dormant Projects, H2 2016 95

Dormant Projects (Contd..1), H2 2016 96

Dormant Projects (Contd..2), H2 2016 97

Dormant Projects (Contd..3), H2 2016 98

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

4SC AG, Acetylon Pharmaceuticals, Inc., Chipscreen Biosciences Ltd, Curis, Inc., GlaxoSmithKline Plc, HitGen LTD, IRBM Science Park SpA, Italfarmaco S.p.A., MEI Pharma, Inc., Merck & Co., Inc., Mirati Therapeutics Inc., Oncolys BioPharma Inc, Sigma-Tau S.p.A., Syndax Pharmaceuticals Inc, TetraLogic Pharmaceuticals

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) Therapeutic Products under Development, Key Players in Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) Therapeutics, Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) Pipeline Overview, Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) Pipeline, Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com